Global Glimepiride Dispersible Tablet Market Size, Share, and COVID-19 Impact Analysis, By Dosage Strength (1mg, 2mg, 3mg, 4mg, and Others), By Application (Type 1 Diabetes, Type 2 Diabetes, and Others), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 - 2033

Global Glimepiride Dispersible Tablet Market Insights Forecasts to 2033

• The Global Glimepiride Dispersible Tablet Market Size was Estimated at USD 1.05 Billion in 2023
• The Market Size is Expected to Grow at a CAGR of around 7.43% from 2023 to 2033
• The Worldwide Glimepiride Dispersible Tablet Market Size is Expected to reach USD 2.15 Billion by 2033
• Asia Pacific is predicted to Grow at the fastest CAGR throughout the projection period

The Global Glimepiride Dispersible Tablet Market Size is predicted to Exceed USD 2.15 Billion by 2033, Growing at a CAGR of 7.43% from 2023 to 2033. The market growth is accelerated by the increasing incidence of type 2 diabetes mellitus, the growing number of aged populations, innovations in the drug delivery system, rising cases of swallowing disorders in older adults, and the proliferation in awareness of the chronic conditions, pharmaceutical companies' spending expenditure in the research and development sectors, and the cost effectiveness of the generic medicines of glimepiride medications.

Market Overview

The glimepiride dispersible tablet market is a part of the pharmaceutical industry that deals with the development, production, and commercialization of the glimepiride dispersible tablets as an oral hypoglycemic agent used in the management of type-2 diabetes with swallowing difficulties. Glimepiride is a sulphonyl urea anti-diabetic class of drug that lowers the blood sugar level by alleviating the insulin level. The mechanistic approach of glimepiride is the inhibition of the ATP-dependent potassium channels, which leads to the depolarization results in to the activation of the voltage-dependent calcium channels and exocytosis of the insulin in to the bloodstream occurs.

Glimepiride is considered an excellent drug molecule as an orally disintegrating tablet for the oral route of administration owing to its low quantity of dose and tastelessness. Deglutination (swallowing) disorders such as dysphagia are mostly seen in diabetic patients, particularly in the geriatric population. Furthermore, orally disintegrating tablets are the premium alternatives for patients with dysphagia as these tablets are dissolved in the oral cavity through saliva as a disintegrating medium.

The rising prevalence of diabetes among the worldwide population escalates the need for medical treatment for the management of diabetes, which results in the rising demand for the anti-diabetic medications leading to the expansion of the glimepiride market growth. For instance, the Government of the United States, Centers for Disease Control and Prevention (CDC) published a National Diabetes Statistic report, which states that in 2021, 38.4 million of the US population were estimated to have diabetes, and 29.7 million of the US population were estimated as having diagnosed diabetes. The market for glimepiride dispersing tablets is expanding due to technological developments in drug formulation and manufacturing methods, such as taste-masking technologies and improved bioavailability. Furthermore, market expansion is facilitated by government policies and regulatory approvals.

Report Coverage

This research report categorizes the global glimepiride dispersible tablet market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyzes the key growth drivers, opportunities, and challenges influencing the global glimepiride dispersible tablet market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the global glimepiride dispersible tablet market.

Driving Factors:

Rising prevalence of type 2 diabetes:

Type 2 diabetes is the most common form of diabetes, resulting from insulin resistance in the pancreas. This condition causes blood glucose levels to rise when there is insufficient insulin to balance them. The additional factors that lead to a rise in the prevalence of type 2 diabetes are sedentary lifestyles, genetic factors or familial history, lack of physical activity, obesity, poor diet, and smoking. The increasing number of the diagnostic procedures or diagnosis of type 2 diabetes is leading to the rise in the demand for anti-diabetic medications such as glimepiride drugs resulting in to the market expansion.

Increasing magnitude of geriatric population:

The geriatric population is at high risk of type 2 diabetes ascribed to the weakened immunity, weight gain and deposition of visceral fat near abdominal region due to lack of exercise, alterations in the insulin hormonal level, disruption in the sleep patterns affects the blood sugar level, taking secondary medications for the management of the diseases such as corticosteroids and antipsychotics can interfere with the blood sugar levels, age-related loss of the muscle strength decreases the insulin sensitivity. Swallowing conditions as dysphagia are more common in the aged population due to weakened oesophageal muscle activity, which accelerates the demand of the dispersible tablets of oral hypoglycaemic agents, and the growing need for medical treatment of diabetes results in the growth of the market. For instance, the data published in the Diabetes Research and Clinical Practice Journal reveals that in 2019, 19.3% of people aged 65-99 years had diabetes, with the number projected to reach 195.2 million by 2030 and 276.2 million by 2045. The North America and Caribbean regions had the highest prevalence at 27.0%, while China, the United States, and India had the highest number of people over 65 with diabetes.

Restraining Factors

The side effects of glimepiride, such as hypoglycemia and weight gain, and availability of the alternative medications for the management of type 2 diabetes, including SGLT 2 inhibitors, and GLP-1 receptor agonist may hinder the growth of the market.

Market Segmentation

The global glimepiride dispersible tablet market share is classified into dosage strength, application, and distribution channel.

• The 1mg segment dominated the global glimepiride dispersible tablet market in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period.

Based on the dosage strength, the global glimepiride dispersible tablet market is categorized into 1mg, 2mg, 3mg, 4mg, and others. Among these, the 1mg segment dominated the global glimepiride dispersible tablet market in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period. The segment growth is accelerated by the rising prevalence of type 2 diabetes mellitus, effective management of the type 2 diabetic condition, aids in lowering blood sugar level and increases the insulin level in the body, prevents from the long-term complications of diabetes such as nerve problems, kidney damage, as glimepiride are formulated in the novel drugs delivery system as dispersible tablets which results in the ease of administration. These types of tablets are useful in geriatric patients having difficulties in swallowing or having deglutination disorders.

• The type 2 diabetes segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the application, the global glimepiride dispersible tablet market is categorized into type 1 diabetes, type 2 diabetes, and others. Among these, the type 2 diabetes segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segmental expansion is attributed to the rising prevalence of type 2 diabetes mellitus, sedentary lifestyle, lack of physical activity, familial history, obesity, and the rising proportion of the geriatric population.

• The hospital pharmacies segment held the largest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the distribution channel, the global glimepiride dispersible tablet market is categorized into online pharmacies, hospital pharmacies, retail pharmacies, and others. Among these, the hospital pharmacies segment held the largest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. This segment dominance is attributed to the provision of the suggestions to patients and doctors for the effective use of medicine, compounding and dispensing anti-diabetic medications facilities, availability of the skilled pharmacist that counsels the patient regarding the management of disease and the dosage regimen of the medications.

Regional Segment Analysis of the Global Glimepiride Dispersible Tablet Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global glimepiride dispersible tablet market over the predicted timeframe.

North America is anticipated to hold the largest share of the global glimepiride dispersible tablet market over the predicted timeframe. This is ascribed to the rising cases of diabetes among North Americans and spending expenditures on the healthcare facilities. In North America, the United States is dominating owing to its rising prevalence of diabetes and increasing geriatric population. Technological advancements are one of the major contributing factors for the expansion of the glimepiride dispersible tablet market in North America. Innovations in the formulation of the tablets and focusing the targeted drug delivery system results in the demand of the glimepiride dispersible tablets which results to growth of the market.

Asia Pacific is anticipated to grow at the fastest CAGR throughout the projected timeframe. This is attributed to the rapid industrialization of pharmaceutical companies, and type 2 diabetes is becoming more common among the population in Asia Pacific. The growth of this market in Asia Pacific is facilitated by government initiatives, improved healthcare infrastructure, and increasing need for antidiabetic medications such as glimepiride for the management of type 2 diabetes mellitus.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global glimepiride dispersible tablet market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Aurobindo Pharma Ltd.
• Intas Pharmaceuticals Ltd.
• Novartis AG
• Zydus Cadila
• Aventis Pharma Limited
• Alkem Laboratories Ltd.
• Hetero Drugs Ltd.
• Torrent Pharmaceuticals, Ltd.
• Biocon Limited
• Sun Pharmaceuticals Ltd.
• Glenmark Pharmaceuticals Ltd.
• Cipla Limited
• Mankind Pharma Ltd.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In June 2024, Sun Pharma Laboratories received the approval from the Subject Expert Committee functional under the Central Drug Standard Control Organizations (CDSCO) to conduct the Phase IV clinical trial of the Phase IV clinical trial of the fixed dose combination (FDC) antidiabetic drug Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin plus Glimepiride plus Extended-Release Metformin Hydrochloride Tablets (10mg + 1mg + 1000mg) and (10mg + 2mg+ 1000mg) Tablets.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global glimepiride dispersible tablet market based on the below-mentioned segments:

Global Glimepiride Dispersible Tablet Market, By Dosage Strength

• 1mg
• 2mg
• 3mg
• 4mg
• Others

Global Glimepiride Dispersible Tablet Market, By Application

• Type 1 Diabetes
• Type 2 Diabetes
• Others

Global Glimepiride Dispersible Tablet Market, By Distribution Channel

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies
• Others

Global Glimepiride Dispersible Tablet Market, By Region

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa